Affordable Access

deepdyve-link
Publisher Website

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Authors
  • Adam, Julien1
  • Planchard, David2
  • Marabelle, Aurélien3
  • Soria, Jean-Charles4
  • Scoazec, Jean-Yves5
  • Lantuéjoul, Sylvie6
  • 1 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. Electronic address: [email protected] , (France)
  • 2 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Département de médecine, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. , (France)
  • 3 DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U1015, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. , (France)
  • 4 Inserm U981, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; DITEP Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France. , (France)
  • 5 Département de biologie et pathologie médicales, Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Faculté de médecine, université Paris Saclay, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre cedex, France. , (France)
  • 6 Département de biopathologie, MESOPATH, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Université Joseph-Fourier, Inserm U823, institut Albert-Bonniot, Grenoble, France. , (France)
Type
Published Article
Journal
Annales de Pathologie
Publisher
Elsevier
Publication Date
January 2016
Volume
36
Issue
1
Pages
94–102
Identifiers
DOI: 10.1016/j.annpat.2015.11.004
PMID: 26778219
Source
Medline
Keywords
License
Unknown

Abstract

Therapies targeting immune checkpoints, in particular programmed death 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), are major new strategies for the treatment of several malignancies including mestatatic non-small cell lung cancer (NSCLC). The identification of predictive biomarkers of response is required, considering efficacy, cost and potential adverse events. Expression of PD-L1 by immunohistochemistry has been associated with higher response rate and overall survival in several clinical trials evaluating anti-PD-1 and anti-PD-L1 monoclonal antibodies. Thus, PD-L1 immunohistochemical companion assays could be required for treatment with some of these therapies in NSCLC. However, heterogeneity in methodologies of PD-L1 assays in terms of primary antibodies and scoring algorithms, and tumor heterogenity for PD-L1 expression are important issues to be considered. More studies are required to compare the different assays, ensure their harmonization and standardization and identify the optimal conditions for testing. PD-L1 expression is likely an imperfect predictive biomarker for patient selection and association with other markers of the tumor immune microenvironment will be probably necessary in the future.

Report this publication

Statistics

Seen <100 times